SuperworthAirsculpt Technologies profit margin AIRS
Gross, operating and net profit as a share of revenue over the last twelve months, from 2021.
- Net margin, 12 months
- −7.8%
- Operating margin, 12 months
- −8.4%
- Net margin on a year earlier
- +0.9 pts
- Peer median
- 6.8%
Over the twelve months to Jun 30, 2026, Airsculpt Technologies kept −7.8% of its revenue as net profit, with an operating margin of −8.4% and a gross margin of 59.7%.
The median for 10 healthcare stocks of a similar size is 6.8%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −7.7% | −7.6% | 59.4% |
| FY2024 | −4.4% | −1.0% | 60.5% |
| FY2023 | −2.3% | 4.8% | 62.2% |
| FY2022 | −8.7% | −2.7% | 62.8% |
| FY2021 | 7.9% | 11.8% | 66.6% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −7.8% | +0.9 pts | −8.4% | |
| Q1 FY26 | −7.4% | +2.4 pts | −7.8% | |
| Q4 FY25 | −7.7% | −3.2 pts | −7.6% | |
| Q3 FY25 | −11.3% | −7.1 pts | −9.3% | |
| Q2 FY25 | −8.6% | −6.9 pts | −5.2% | |
| Q1 FY25 | −9.8% | −10.6 pts | −8.4% | |
| Q4 FY24 | −4.4% | −2.2 pts | −1.0% | |
| Q3 FY24 | −4.1% | −0.4 pts | 2.0% | |
| Q2 FY24 | −1.8% | +5.3 pts | 4.3% | |
| Q1 FY24 | 0.8% | +8.8 pts | 9.5% | |
| Q4 FY23 | −2.3% | +6.4 pts | 4.8% | |
| Q3 FY23 | −3.8% | +9.3 pts | 1.1% |
Against its peers
Companies in Healthcare nearest Airsculpt Technologies' size, closest first, today.
| Company | Profit margin |
|---|---|
| AIRSAirsculpt Technologies | −7.8% |
| ICCCImmucell | 2.6% |
| KEQUKewaunee Scientific | 3.0% |
| LFVNLifevantage | 2.8% |
| SPROSpero Therapeutics | 15.7% |
| APTAlpha Pro Tech | 6.8% |
| ATNMActinium Pharmaceuticals | n/m |
| NEPHNephros | 8.4% |
| PDEXPro DEX | 17.6% |
| PLXProtalix BioTherapeutics | 23.5% |
| NATRNatures Sunshine Products | 3.7% |
| Peer median | 6.8% |
Where Airsculpt Technologies ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Airsculpt Technologies
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.